Cell Death and DifferentiationCancer BiologyPeer-reviewed journal article
Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms
Maria DaverniD, Cole J. Turner, Daryl GriffiniD, Lara Bencsics, Brenda C. Chan, Jasmine Yun-Tong KungiD, Michael OlsoniD, Cheyanne Walker-WilliamsiD, Shaili Soni, Leah Krotee, Michael YorsziD, Gabriella AntonellisiD, Patrick Hall LizotteiD, Cloud Peter PaweletziD, Jeremy A. RyaniD, Filippo BirocchiiD, Antonio J. AlmazaniD, Kristopher A. SarosiekiD, David Allen BarbieiD, Patrick D. BholaiD, Marcela Valderrama MausiD, Anthony G. LetaiiD
- Citations
- 7
- FWCI
- 2.09
- Field percentile
- top 12%
Abstract
Persisters are a rare sub-population of tumor cells that survive anti-cancer therapy and are thought to be a major cause of recurrence. These cells have been identified following both drug- and immune-therapy but are generally considered to be distinct entities. Since both pharmacological agents and immune cells often kill via apoptosis, we tested a hypothesis that both types of cells survive based on reduced mitochondrial apoptotic sensitivity, which in turn would yield a similar and reciprocal multi-agent resistant phenotype. Supporting this hypothesis, we indeed observed that IPCs acquired a reduced sensitivity to multiple drug classes and radiotherapy, suggesting non-immune mechanisms are important in the survival of cancer cells after immunotherapy. Likewise, DTPs developed not only a reduced sensitivity to multiple drug classes and radiotherapy, but also acquired a reduced sensitivity to T cell killing. Both IPCs and DTPs developed a decreased sensitivity to mitochondrial apoptosis. A sub-population of IPCs downregulated antigen and upregulated PD-L1. Intriguingly, in the IPCs that didnt employ these mechanisms of resistance, a greater decrease in sensitivity to mitochondrial apoptosis was observed, suggesting that the presence or absence of a resistance mechanism can exert selective pressures over the emergence of others. Targeting anti-apoptotic dependencies in persisters increased sensitivity to chemotherapy or CAR T therapy. These results suggest that common biological mechanisms underly survival of persisters, whether derived from immune or drug therapy, and offer an explanation for the acquired cross-resistance to these two types of therapies often observed in the clinic. HighlightsO_LIImmunotherapy persister cells (IPCs) are less sensitive to drugs and radiation. C_LIO_LIDrug tolerant persisters (DTPs) are less sensitive to radiation and CAR T cell attack. C_LIO_LIIPCs and DTPs are less sensitive to mitochondrial apoptosis. C_LIO_LITargeting anti-apoptotic dependencies helps eliminate IPCs/DTPs. C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/641492v2_ufig1.gif" ALT="Figure 1"> View larger version (52K): org.highwire.dtl.DTLVardef@fe98b4org.highwire.dtl.DTLVardef@db7bfdorg.highwire.dtl.DTLVardef@1a94469org.highwire.dtl.DTLVardef@1ca6b2c_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antigenic cancer persister cells survive direct T cell attack
Michael Wang, Brandon E. Mauch, … Matthew J. Hangauer·bioRxiv·Mar 14, 2025
- Heterogeneous, Population-Level Drug-Tolerant Persisters Exhibit Ion-Channel Remodeling and Ferroptosis Susceptibility
Corey E. Hayford, Blake Baleami, … Leonard A. Harris·bioRxiv·Feb 3, 2022
- Inheritable cell-states shape drug-persister correlations and population dynamics in cancer cells
Anton Iyer, Adrian Alva, … Shaon Chakrabarti·PLoS Computational BiologyPeer-reviewed·Sep 19, 2025
- Pharmacological Induction of Irreversible Senescence in Drug-Tolerant Persister Cells Prevents Tumor Relapse
Bowen Wang, Yun Zhi, … Sheng Ding·bioRxiv·Oct 10, 2025
- CDKN1B (p27kip1) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitors.
E. Horwitz, T. D. Dubash, … D. A. Haber·bioRxiv·Feb 20, 2024
- Transient cell-in-cell formation underlies tumor resistance to immunotherapy
A. Gutwillig, N. Santana-Magal, … Y. Carmi·bioRxiv·Sep 10, 2020